Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ

Part 1- Advanced Solid Tumors Clinical Trial

Official title: A Multicenter, Phase 1/1b, Open Label Study Evaluating the Safety, Tolerability and Pharmacokinetics of Rilotumumab in Japanese Subjects

Status Completed

Clinical Trial Summary

This is an open label phase 1/1b study of Rilotumumab in Japanese subjects with advanced solid tumors or metastatic gastric esphagogastric (GEJ) adenocarcinoma.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Part 1- Advanced Solid Tumors
• Part 2- Advanced or Metastatic Gastric Cancer
• Part 2- Advanced or Metastatic GEJ
• Stomach Neoplasms

• NCT number: NCT01791374
• Study type: Interventional
• Source: Amgen
• Status: Completed
• Phase: Phase 1
• Start date: November 2012
• Completion date: March 2015